Joshua A. Roth, PHD, MHA

Joshua A. Roth, PHD, MHA

Assistant Member, Cancer Prevention Program
Public Health Sciences Division
Assistant Professor, Department of Pharmacy
University of Washington

Education

Union College, Schenectady, NY, 2000-2004, BS (Psychology)
University of Washington, Seattle, WA, 2006-2008, MHA (Health Services Administration)
University of Washington, Seattle, WA, 2008-2012, PhD (Pharmaceutical Outcomes Research & Policy)

Research Focus

Application of comparative effectiveness research and patient-centered outcomes research methods to inform translation of lung, breast, and prostate cancer diagnostics and therapeutics, including: observational study design, decision modeling, randomized controlled trial design, systematic review and meta-analysis.

Current Studies

My current research focuses on evaluating comparative effectiveness and patient perspectives in lung cancer screening. Recent evidence from the National Lung Screening Trial demonstrated that low-dose computed tomography (LDCT) lung cancer screening resulted in a 20% reduction in lung cancer mortality vs. x-ray screening. Based largely on this finding, guidelines from the U.S. Preventive Services Task Force (USPSTF) and National Comprehensive Cancer Network (NCCN) were updated to recommend annual LDCT lung cancer screening for millions of heavy smokers in the United States. LDCT lung cancer screening is now a covered preventative service in the vast majority of U.S. health insurance plans, and healthcare systems across the U.S. are developing programs to offer screening to eligible plan members. This type of large-scale change in medical practice will involve many complex decisions between alterative strategies and medical technologies. The overall objective of my research is to measure and interpret the outcomes of these alternative strategies and medical technologies using a range of comparative effectiveness research and patient-centered outcomes research methods.

Current Study Titles Include:

  • Patient Experiences with Lung CAncer Screening (PELiCANS): A qualitative analysis to evaluate patient perspectives about lung cancer screening in an integrated healthcare system
  • Development of an algorithm to predict treatment complications and mortality in patients with early-stage lung cancer receiving treatment with curative intent
  • Evaluation of the potential radiation exposure harms of long-term low-dose computed tomography lung cancer screening
  • The potential clinical, resource use, and fiscal impacts of Lung-RADS to inform low-dose CT lung cancer screening in Medicare
  • Medical Overuse Among Traditionally Underserved Patients: Adherence to ASTRO ‘Choosing Wisely’ Recommendations Among Medicare and Commercially Insured Cancer Patients
  • Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in the SWOG 1400 (S1400) Clinical Trial
  • Health Insurance Coverage as a Barrier to Enrollment in Cancer Clinical Trials: A Prospective, Patient-Level Survey of a Cancer Cooperative Clinical Trials Group
  • Healthcare Resource Utilization and Expenditure in Malignant Pleural Mesothelioma: A SEER-Medicare Analysis
     


Additional Links & Information

Related Labs & Projects

View all labs & projects >
Joshua Roth, PhD

Contact Information

Phone
(206) 667-7867
Fax
(206) 667-5597
Email
Additional contact

Mail Stop: M3-B232